The GRS improved the ability to discriminate NAFLD-HCC risk as compared to evaluation of the PNPLA3 I148M variant alone and of a combination of the PNPLA3 I148M and TM6SF2 E167K variants (p < 2*10−16; Fig. 4b and Supplementary Table 5). This evidence concerns the gene TM6SF2 and hepatocellular carcinoma.